INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

INmune Bio (NASDAQ:INMB) posted its earnings results on Thursday. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04, FiscalAI reports.

Here are the key takeaways from INmune Bio’s conference call:

• CORDStrom is moving toward regulatory filing — the company completed a rapid-assessed PIP, started process‑validation manufacturing runs, signed a supply agreement with Anthony Nolan for umbilical cords, and expects to submit the U.K. MAA in early Q3 as it aims for commercial manufacture in 2027.
• XPro development continues with additional MINDFuL imaging analyses (MRI myelin preservation and structural integrity) and the company is exploring rare‑disease trials and partner options to define late‑stage/regulatory paths.
• Operational spending fell this quarter, with net loss narrowing to approximately $5.4 million (from $9.7M) and R&D down to ~$3.6M (from $7.6M), reflecting lower burn compared with the prior year period.
• Cash and equivalents were approximately $21.4 million at March 31, 2026, which management says funds operations only through Q1 2027, indicating a near‑term need for additional financing or partnerships to support commercialization and late‑stage programs.

INmune Bio Price Performance

INmune Bio stock remained flat at $1.43 during mid-day trading on Friday. 240,230 shares of the company were exchanged, compared to its average volume of 249,626. The firm has a market cap of $38.01 million, a P/E ratio of -0.86 and a beta of 1.04. The company’s 50 day moving average price is $1.31 and its 200-day moving average price is $1.53. INmune Bio has a 52 week low of $1.09 and a 52 week high of $11.64.

Hedge Funds Weigh In On INmune Bio

A number of hedge funds have recently bought and sold shares of the company. Jain Global LLC bought a new position in INmune Bio in the 4th quarter worth approximately $66,000. Charles Schwab Investment Management Inc. boosted its position in shares of INmune Bio by 20.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock valued at $78,000 after acquiring an additional 8,427 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of INmune Bio by 269.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 56,477 shares of the company’s stock valued at $88,000 after acquiring an additional 41,173 shares during the last quarter. Oxford Asset Management LLP bought a new position in shares of INmune Bio during the 2nd quarter valued at approximately $52,000. Finally, JPMorgan Chase & Co. boosted its position in shares of INmune Bio by 1,042.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock valued at $169,000 after acquiring an additional 66,700 shares during the last quarter. Institutional investors own 12.72% of the company’s stock.

Analyst Ratings Changes

INMB has been the subject of several research analyst reports. Lucid Cap Mkts upgraded shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. Wall Street Zen lowered shares of INmune Bio from a “hold” rating to a “sell” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, INmune Bio has an average rating of “Hold” and a consensus price target of $8.00.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.